Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  10145 of 10341  at  8/15/2022 12:32:43 AM  by

Biotech2050


 In response to msg 10144 by  JBWIN
view thread

Re: Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018

A KOL involved in Iberdomide and CC-92480 trials is Dr Sagar Lonial and here are his thoughts.
 
Indeed it’s like chessboard moves whilst navigating through Revlimid patent expiration. Given the recent developments (drug pricing reforms initiatives by government) i think BMY will have no option but to accelerate wherever possible their development plans and let iberdomide and CC-92480 cannibalize Revlimid revenues soonest. 
Easier said than done.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10146 Re: Monitoring the developing Multiple Myeloma (MM) chessboard CELG first articulated in May2018 grafzeppelin 10 8/15/2022 7:51:52 AM




Financial Market Data provided by
.
Loading...